The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: Review of a novel anticancer agent

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 73-98

  Mizejewski, Gerald J ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

8 mer fragment; Alpha fetoprotein; Breast cancer; Cell adhesion; Growth inhibitory peptide; Tumor growth

Indexed keywords

ALPHA FETOPROTEIN; AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINE; CARBOXY TERMINAL TELOPEPTIDE; DOPAMINE RECEPTOR; EPITOPE; ESTRADIOL; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; GLUTAMINE; GLYCOPROTEIN E2; GROWTH INHIBITORY PEPTIDE 34; GROWTH INHIBITORY PEPTIDE 8; MITOGEN ACTIVATED PROTEIN KINASE; OCTAPEPTIDE; PROTEIN SERINE KINASE; PROTEIN SH3; SECURIN; SOMATOMEDIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOASSAY; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTACT INHIBITION; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; LIGAND BINDING; MUTATION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; SYNTHESIS; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ALPHA-FETOPROTEINS; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 34247887590     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.343     Document Type: Review

References (111)

1. Geho DH, Liotta LA, Petricoin EF, et al. The amplified peptidome: The new treasure chest of candidate biomarkers. Curr Opin Chem Biol 2006;10:50.
2. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteo 2002;1:845.
3. Ingham KC, Brew SA, Erickson HP. Localization of a cryptic binding site for tenascin on fibronectin. J Biol Chem 2004;279:28132.
4. Podolnikova NP, Yakubenko VP, Volkov GL, et al. Identification of a novel binding site for platelet integrins alpha IIb beta 3 (GPIIbIIIa) and alpha 5 beta 1 in the gamma C-domain of fibrinogen. J Biol Chem 2003;278:32251.
5. Jacobson HI, Bennett JA, Mizejewski GJ. Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res 1990;50:415.
6. Mizejewski G. Review of peptides as receptor ligand drugs and their relationship to G-coupled signal transduction. Exp Opin Invest Drugs 2001;10:1063.
7. Mizejewski GJ, Dias JA, Hauer CR, et al. Alpha-fetoprotein-derived synthetic peptides: Assay of an estrogen-modifying regulatory segment. Mol Cell Endocrinol 1996;118:15.
8. Vakharia D, Mizejewski GJ. Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res Treat 2000;63:41.
9. Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer 1998;75:596.
10. Li MS, Li PF, Yang FY, et al. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res 2002;12:151.
11. Leffert HL, Sell S. Alpha1-fetoprotein biosynthesis during the growth cycle of differentiated fetal rat hepatocytes in primary monolayer culture. J Cell Biol 1974;61:823.
12. Toder V, Blank M, Gold-Gefter L, et al. The effect of alpha-fetoprotein on the growth of placental cells in vitro. Placenta 1983;4:79.
13. Leal JA, May JV, Keel BA. Human alpha fetoprotein enhances epidermal growth factor proliferative activity upon porcine granulosa cells in monolayer culture. Endocrinology 1990;126:669.
14. Keel BA, Eddy KB, Cho S, et al. Synergistic action of purified alpha-fetoprotein and growth factors on the proliferation of porcine granulosa cells in monolayer culture. Endocrinology 1991;129:217.
15. Terentiev AA, Moldogazieva NT. Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc) 2006;71:120.
16. Butterstein GM, Mizejewski GJ. Alpha-fetoprotein inhibits frog metamorphosis: implications for protein motif conservation. Comp Biochem Physiol A Mol Integr Physiol 1999;124:39.
17. Allen SH, Bennett JA, Mizejewski GJ, et al. Purification of alpha-fetoprotein from human cord serum with demonstration of its antiestrogenic activity. Biochim Biophys Acta 1993;1202:135.
18. Vallette G, Vranckx R, Martin ME, et al. Conformational changes in rodent and human alpha-fetoprotein: Influence of fatty acids. Biochim Biophys Acta 1989;997:302.
19. Haourigui M, Thobie N, Martin ME, et al. In vivo transient rise in plasma free fatty acids alters the functional properties of alpha-fetoprotein. Biochim Biophys Acta 1992;1125:157.
20. Benassayag C, Mignot TM, Haourigui M, et al. High polyunsaturated fatty acid, thromboxane A2, and alpha-fetoprotein concentrations at the human feto-maternal interface. J Lipid Res 1997;38:276.
21. Bennett JA, Mizejewski GJ, Allen SHG, et al. Transformation of alpha-fetoprotein to a negative regulator of estrogen-dependent growth by ligands of the steroid/thyroid hormone receptor superfamily. 18th International Congress. J Cancer Res Clin Oncol 1993;34:244.
22. Swartz SK, Soloff MS. The lack of estrogen binding by human alpha-fetoprotein. J Clin Endocrinol Metab 1974;39:589.
23. Mizejewski G, Smith G, Butterstein G. Review and proposed action of alpha-fetoprotein growth-inhibiting peptides as estrogen- and cytoskeletal-associated factors. Intl J Cell Biol 2004;28:913.
24. Zizkovsky V, Strop P, Korcakova J, et al. Fluorescence spectroscopy, fluorescence polarization, and circular dichroism in studies on pH-dependent changes in the alpha-fetoprotein molecule. Ann N Y Acad Sci 1983;417:49.
25. Butterstein G, Morrison J, Mizejewski GJ. Effect of alpha-fetoprotein and derived peptides on insulin- and estrogen-induced fetotoxicity. Fetal Diagn Ther 2003;18:360.
26. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995;267:383.
27. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci U S A 1996;93:13.
28. Mizejewski GJ, MacColl R. Alpha-fetoprotein growth inhibitory peptides: Potential leads for cancer therapeutics. Mol Cancer Ther 2003;2:1243.
29. Muehlemann M, Miller KD, Dauphinee M, et al. Review of growth inhibitory peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis. Cancer Metast Rev 2005;24:441.
30. Mizejewski G, Muehlemann M, Dauphinee MJ. Update of alpha-fetoprotein growth inhibitory peptides as chemotherapeutic agents for tumor growth and metastasis. Chemotherapy 2006;52:83.
31. Mesfin FB, Bennett JA, Jacobson HI, et al. Alpha-fetoprotein-derived antiestrotrophic octapeptide. Biochim Biophys Acta 2000;1501:33.
32. DeFreest LA, Mesfin FB, Joseph L, et al. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: Investigation of the pharmacophore and synthesis optimization. J Pept Res 2004;63:409.
33. Mizejewski GJ. Alpha-fetoprotein structure and function: Relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 2001;226:377.
34. Spanjaard RA, Darling DS, Chin WW. Ligand-binding and heterodimerization activities of a conserved region in the ligand-binding domain of the thyroid hormone receptor. Proc Natl Acad Sci U S A 1991;88:8587.
35. Wurtz JM, Bourguet W, Renaud JP, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 1996;3:87.
36. Wang XP, Wang QX, Li HY, et al. Heat shock protein 70 chaperoned alpha-fetoprotein in human hepatocellular carcinoma cell line BEL-7402. W J Gastroenterol 2005;11:5561.
37. De Los Rios P, Ben-Zvi A, Slutsky O, et al. Hsp70 chaperones accelerate protein translocation and the unfolding of stable protein aggregates by entropic pulling. Proc Natl Acad Sci U S A 2006;103:6166.
38. Jean-Pierre C, Perni SC, Bongiovanni AM, et al. Extracellular 70-kd heat shock protein in mid-trimester amniotic fluid and its effect on cytokine production by ex vivo-cultured amniotic fluid cells. Am J Obstet Gynecol 2006;194:694.
39. Luk JM, Lam CT, Siu AF, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) upregulation and their associated prognostic values. Proteomics 2006;6:1049.
40. Mizejewski GJ, Vonnegut M. Induction of fetal wastage in pregnant mice passively immunized to murine alpha-fetoprotein. Dev Comp Immunol 1983;7:139.
41. Mizejewski GJ, Vonnegut M, Jacobson HI. Studies of the intrinsic antiuterotropic activity of murine alpha-fetoprotein. Tumour Biol 1986;7:19.
42. Mizejewski GJ. An apparent dimerization motif in the third domain of alpha-fetoprotein: Molecular mimicry of the steroid/thyroid nuclear receptor superfamily. Bioessays 1993;15:427.
43. Mizejewski GJ. Alpha-fetoprotein binding proteins: Implications for transmembrane passage and subcellular localization. Life Sci 1995;56:1.
44. Mizejewski GJ. Alpha-fetoprotein as a biologic response modifier: Relevance to domain and subdomain structure. Proc Soc Exp Biol Med 1997;215:333.
45. Mesfin FB, Andersen TT, Jacobson HI, et al. Development of a synthetic cyclized peptide derived from alpha-fetoprotein that prevents the growth of human breast cancer. J Pept Res 2001;58:246.
46. Mizejewski G, Vakharia D, Richardson BE. Binding of a human alpha-fetoprotein fragment to the estrogen receptor. In: AAAS Annual Meeting, Anaheim, CA, January 21, 1999.
47. Bennett JA, Mesfin FB, Andersen TT, et al. A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci U S A 2002;99:2211.
48. Parikh RR, Gildener-Leapman N, Narendran A, et al. Prevention of N-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP. Clin Cancer Res 2005;11:8512.
49. Eisele LE, Mesfin FB, Bennett JA, et al. Studies on a growth-inhibitory peptide derived from alpha-fetoprotein and some analogs. J Pept Res 2001;57:29.
50. Eisele LE, Mesfin FB, Bennett JA, et al. Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties. J Pept Res 2001;57:539.
51. MacColl R, Eisele LE, Stack RF, et al. Interrelationships among biological activity, disulfide bonds, secondary structure, and metal ion binding for a chemically synthesized 34-amino-acid peptide derived from alpha-fetoprotein. Biochim Biophys Acta 2001;1528:127.
52. Butterstein G, MacColl R, Mizejewski GJ, et al. Biophysical studies and antigrowth activities of a peptide, a certain analog, and a fragment peptide derived from alpha-fetoprotein. J Pept Res 2003;61:213.
53. Kates SA, Sole NA, Johnson CR, et al. A novel convenient three-dimensional orthogonal strategy for solid-phase synthesis of cyclic peptides. Tetrahed Lett 1993;34:1549.
54. Dauphinee MJ, Mizejewski GJ. Human alpha-fetoprotein contains potential heterodimerization motifs capable of interaction with nuclear receptors and transcription/growth factors. Med Hypoth 2002;58:453.
55. Nguyen JT, Turck CW, Cohen FE, et al. Exploiting the basis of proline recognition by SH3 and WW domains: Design of N-substituted inhibitors. Science 1998;282:2088.
56. Boelaert K, Yu R, Tannahill LA, et al. PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol 2004;33:663.
57. Zamora-Leon SP, Bresnick A, Backer JM, et al. Fyn phosphorylates human MAP-2c on tyrosine 67. J Biol Chem 2005;280:1962.
58. Hauck CR, Hunter T, Schlaepfer DD. The v-Src SH3 domain facilitates a cell adhesion-independent association with focal adhesion kinase. J Biol Chem 2001;276:17653.
59. Solomaha E, Szeto FL, Yousef MA, et al. Kinetics of Src homology 3 domain association with the proline-rich domain of dynamins: specificity, occlusion, and the effects of phosphorylation. J Biol Chem 2005;280:23147.
60. Choowongkomon K, Carlin CR, Sonnichsen FD. A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor. J Biol Chem 2005;280:24043.
61. Ferguson MR, Fan X, Mukherjee M, et al. Directed discovery of bivalent peptide ligands to an SH3 domain. Protein Sci 2004;13:626.
62. Liu G, Nozell S, Xiao H, et al. DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 2004;24:487.
63. Nozell S, Wu Y, McNaughton K, et al. Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene 2003;22:4333.
64. Baptiste N, Friedlander P, Chen X, et al. The proline-rich domain of p53 is required for cooperation with antineoplastic agents to promote apoptosis of tumor cells. Oncogene 2002;21:9.
65. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996;93:15335.
66. Zhu J, Jiang J, Zhou W, et al. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 1999;18:2149.
67. Foray N, Marot D, Randrianarison V, et al. Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation. Mol Cell Biol 2002;22:4020.
68. Doong H, Price J, Kim YS, et al. CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70. Oncogene 2000;19:4385.
69. Khan MM, Hadman M, Wakade C, et al. Cloning, expression, and localization of MNAR/PELP1 in rodent brain: Colocalization in estrogen receptor-alpha-but not in gonadotropin-releasing hormone-positive neurons. Endocrinology 2005;146:5215.
70. Barletta F, Wong CW, McNally C, et al. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 2004;18:1096.
71. Bennett JA, DeFreest L, Anaka I, et al. AFPep: An antibreast cancer peptide that is orally active. Breast Cancer Res Treat 2006;98:133.
72. Zhou HX. Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains. Biophys J 2006;91:3170.
73. Feller SM, Ren R, Hanafusa H, et al. SH2 and SH3 domains as molecular adhesives: The interactions of Crk and Abl. Trends Biochem Sci 1994;19:453.
74. Alexandropoulos K, Cheng G, Baltimore D. Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc Natl Acad Sci U S A 1995;92:3110.
75. Mizejewski GJ, Warner AS. Alpha-fetoprotein can regulate growth in the uterus of the immature and adult ovariectomized mouse. J Reprod Fertil 1989;85:177.
76. Mizejewski GJ, Butterstein G. Survey of functional activities of alpha-fetoprotein-derived growth inhibitory peptides: Review and prospects. Curr Protein Pept Sci 2006;7:73.
77. Villacampa MJ, Lampreave F, Calvo M, et al. Incorporation of radiolabelled alphafetoprotein in the brain and other tissues of the developing rat. Brain Res 1984;314:77.
78. Naval J, Villacampa MJ, Goguel AF, et al. Cell-type-specific receptors for alpha-fetoprotein in a mouse T-lymphoma cell line. Proc Natl Acad Sci U S A 1985;82:3301.
79. Suzuki Y, Zeng CQ, Alpert E. Isolation and partial characterization, of a specific alpha-fetoprotein receptor on human monocytes. J Clin Invest 1992;90:1530.
80. Alava MA, Iturralde M, Lampreave F, et al. Specific uptake of alpha-fetoprotein and albumin by rat Morris 7777 hepatoma cells. Tumour Biol 1999;20:52.
81. Moro R, Tamaoki T, Wegmann TG, et al. Monoclonal antibodies directed against a widespread oncofetal antigen: The alpha-fetoprotein receptor. Tumour Biol 1993;14:116.
82. Laderoute M, Willans D, Wegmann T, et al. The identification, isolation, and characterization of a 67 kilodalton, PNA-reactive autoantigen commonly expressed in human adenocarcinomas. Anticancer Res 1994;14:1233.
83. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988;59:44.
84. Knighton D, Ausprunk D, Tapper D, et al. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 1977;35:347.
85. DeFreest LA. Inhibition of breast cancer growth by AFP-derived peptide: Study of mechanism. Albany Medical College Graduate Studies Poster Session, Abstract, Albany, NY: 2005:5.
86. Bui LA, Butterfield LH, Kim JY, et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 1997;8:2173.
87. Vollmer CM, Jr, Eilber FC, Butterfield LH, et al. Alpha-fetoprotein- specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999;59:3064.
88. Butterfield LH, Meng WS, Koh A, et al. T-cell responses to HLA-A*0201-restricted peptides derived from human-alpha-fetoprotein. J Immunol 2001;166:5300.
89. + patients with hepatocellular carcinoma. Int J Cancer 2006;118:1194.
90. Hanke P, Rabe C, Serwe M, et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 2002;37:949.
91. Meng WS, Butterfield LH, Ribas A, et al. alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001;61:8782.
92. Butterfield LH, Koh A, Meng W, et al. Generation of human T-Cell Responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 1999;59:3134.
93. Meng WS, Butterfield LH, Ribas A, et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T-cell epitope derived from human alpha-fetoprotein. Mol Immunol 2000;37:943.
94. Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 2004;127:S232.
95. Um SH, Mulhall C, Alisa A, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004;173:1772.
96. Gierthy JF, Lincoln DW, 2nd, Roth KE, et al. Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells. J Cell Biochem 1991;45:177.
97. Gierthy JF, Bennett JA, Bradley LM, et al. Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 1993;53:3149.
98. DePasquale JA, Samsonoff WA, Gierthy JF. 17-beta-estradiol-induced alterations of cell-matrix and intercellular adhesions in a human mammary carcinoma cell line. J Cell Sci 1994;107(Pt. 5):1241.
99. Richardson BE, Hulka BS, Peck JL, et al. Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 1998;148:719.
100. Melbye M, Wohlfahrt J, Lei U, et al. alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst 2000;92:1001.
101. Locati M, Torre YM, Galliera E, et al. Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Cytokine Growth Fact Rev 2005;16:679.
102. Shen H, Schuster R, Stringer KF, et al. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. Faseb J 2006;20:59.
103. de Brevern AG, Wong H, Tournamille C, et al. A structural model of a seven-transmembrane helix receptor: The Duffy antigen/receptor for chemokine (DARC). Biochim Biophys Acta 2005;1724:288.
104. Hamza A, Sarma MH, Sarma RH. Plausible interaction of an alpha-fetoprotein cyclopeptide with the G-protein-coupled receptor model GPR30: Docking study by molecular dynamics simulated annealing. J Biomol Struct Dyn 2003;20:751.
105. Thomas P, Pang Y, Filardo EJ, et al. Identity of an estrogen membrane receptor coupled to a G-protein in human breast cancer cells. Endocrinology 2005;146:624.
106. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002;80:231.
107. 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004;279:27008.
108. Hepler JR. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999;20:376.
109. Zhong H, Neubig RR. Regulator of G-protein-signaling proteins: Novel multifunctional drug targets. J Pharmacol Exp Ther 2001;297:837.
110. Siderovski DP, Strockbine B, Behe CI. Whither goest the RGS proteins? Crit Rev Biochem Mol Biol 1999;34:215.
111. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: Prospects for anticancer therapy. Exp Rev Anticancer Ther 2002;2:709.